Your browser doesn't support javascript.
Challenges in diagnosing hydroxychloroquine myopathy during the COVID-19 pandemic.
Pamphlett, Roger; Wang, Min-Xia; Chan, Renee Cf.
  • Pamphlett R; Department of Neuropathology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Wang MX; Discipline of Pathology, School of Medical Sciences, Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Chan RC; Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Intern Med J ; 50(12): 1559-1562, 2020 12.
Article in English | MEDLINE | ID: covidwho-991429
ABSTRACT
Hydroxychloroquine is being used for COVID-19 symptoms and in clinical trials, but can cause a toxic myopathy that leads to muscle weakness. A review of skeletal muscle biopsies from patients with hydroxychloroquine myopathy gives pointers of steps that can be taken to diagnose this toxic myopathy early and help differentiate it from COVID-19-related muscle weakness.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Muscle Weakness / COVID-19 / Hydroxychloroquine / Muscular Diseases Type of study: Diagnostic study / Prognostic study Limits: Adult / Aged / Humans / Middle aged Language: English Journal: Intern Med J Journal subject: Internal Medicine Year: 2020 Document Type: Article Affiliation country: Imj.15092

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Muscle Weakness / COVID-19 / Hydroxychloroquine / Muscular Diseases Type of study: Diagnostic study / Prognostic study Limits: Adult / Aged / Humans / Middle aged Language: English Journal: Intern Med J Journal subject: Internal Medicine Year: 2020 Document Type: Article Affiliation country: Imj.15092